Collegium to acquire Ironshore Therapeutics for $525M; Jornay PM ADHD drug; Q2 prelim rev $145M

COLLEGIUM PHARMACEUTICAL, INC

Acquires Ironshore for $525M cash plus up to $25M milestone if Jornay PM net revenue exceeds defined 2025 threshold.
Jornay PM (ADHD) expected >$100M net revenue in 2024; H1 2024 prescriptions up 32% YoY.
Funded by cash on hand and new $646M five-year Pharmakon loan with 300bps rate reduction.
Preliminary Q2 2024 net product revenue $145M (+7% YoY); reaffirms FY2024 guidance of $580-595M revenue, $380-395M adj EBITDA.
Director Neil McFarlane resigned immediately due to conflict of interest (CEO of Zevra Therapeutics).

item 1.01 item 2.02 item 2.03 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Neil McFarlane

director

COLL · COLLEGIUM PHARMACEUTICAL, INC

Effective: 2024-07-28
Filed: July 29, 2024, 7:59 PM ET

On July 28, 2024, Neil McFarlane notified the board of directors of the Company (the “Board”) of his intent to resign from the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Neil McFarlane resigned as director at COLLEGIUM PHARMACEUTICAL, INC.

Action: resigned
Role: director

Exact text from the filing

On July 28, 2024, Neil McFarlane notified the board of directors of the Company (the “Board”) of his intent to resign from the Board, effective immediately.

View on SEC.gov

COLLEGIUM PHARMACEUTICAL, INC filing history →

Source: SEC EDGAR

accession 0001104659-24-083126

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.